Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Akebia Therapeutics
(NQ:
AKBA
)
1.530
+0.060 (+4.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Akebia Therapeutics
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 04, 2022
Gainers Oncternal Therapeutics (NASDAQ:ONCT
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 30, 2021
Gainers Kiora Pharmaceuticals (NASDAQ:KPRX) stock moved upwards by 20.4% to $1.06 during Thursday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
Akebia Therapeutics, inc (AKBA) Q3 2021 Earnings Call Transcript
November 09, 2021
AKBA earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
August 20, 2021
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by...
Via
Benzinga
Exposures
Product Safety
99 Biggest Movers From Yesterday
August 06, 2021
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...
Via
Benzinga
Akebia Therapeutics, inc (AKBA) Q2 2021 Earnings Call Transcript
August 05, 2021
AKBA earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Akebia Therapeutics Stock Is Soaring Today
August 05, 2021
Investors liked what they heard in the company's Q2 update.
Via
The Motley Fool
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
July 27, 2021
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger
July 26, 2021
From
Robbins LLP
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 16, 2021
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
July 15, 2021
Gainers Akebia Therapeutics (NASDAQ:AKBA...
Via
Benzinga
Akebia Therapeutics Insights: Return On Capital Employed
June 21, 2021
During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. In Q4, Akebia...
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
June 18, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Cramer Gives His Opinion On Novavax, Exact Sciences And More
June 08, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he prefers Moderna Inc (NASDAQ: MRNA) over Novavax, Inc. (NASDAQ: NVAX). Philip Morris International Inc. (...
Via
Benzinga
Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise
June 04, 2021
Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the...
Via
Benzinga
Looking Into Akebia Therapeutics's Return On Capital Employed
June 01, 2021
During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. Akebia...
Via
Benzinga
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
June 01, 2021
Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 01, 2021
Gainers Paratek Pharmaceuticals (NASDAQ:PRTK) stock increased by 12.65% to $9.26 during Tuesday's pre-market session. The company's market cap stands at $434.5...
Via
Benzinga
Akebia Therapeutics, Inc. (NASDAQ: AKBA) Investor Alert: Investigation over Potential Wrongdoing
May 10, 2021
San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares over potential wrongdoing at Akebia Therapeutics, Inc was announced...
Via
SBWire
Recap: Akebia Therapeutics Q1 Earnings
May 10, 2021
Shares of Akebia Therapeutics (NASDAQ:AKBA) fell 1.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 4.26% year over...
Via
Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
28 Stocks Moving in Thursday's Pre-Market Session
April 29, 2021
Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 39.6% to $9.23 in pre-market trading after the company disclosed updated data from its randomized, multicenter, placebo-...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.